Literature DB >> 16699496

Transformation-specific matrix metalloproteinases, MMP-7 and MMP-13, are present in epithelial cells of keratoacanthomas.

Tiina T Kuivanen1, Leila Jeskanen, Lauri Kyllönen, Ulla Impola, Ulpu K Saarialho-Kere.   

Abstract

Keratoacanthomas are rapidly growing hyperproliferative skin tumors that may clinically or histologically be difficult to distinguish from well-differentiated squamous cell cancers (SCCs). UV light, trauma, and immune suppression represent their etiological factors. As matrix metalloproteinases (MMPs) are implicated at all stages of tumorigenesis, we investigated the expression profile of several cancer-related MMPs to find markers that would differentiate keratoacanthomas from SCCs and shed light to the pathobiology of keratoacanthoma. Samples from 31 keratoacanthomas and 15 grade I SCCs were studied using immunohistochemistry for MMP-2, -7, -8, -9, -10, -13, and -19 and p16 and laminin-5gamma2 chain. In situ hybridization for MMP-7, -10, and -13 was performed in a subset of tumors. Keratinocytes with atypia, presence of neovascularization, and composition of the inflammatory infiltrate were graded from hematoxylin-eosin stainings. MMP-7 was present in the epithelium of 4/31 keratoacanthomas and 9/15 SCCs, MMP-8 in 3/30 keratoacanthomas and 0/15 SCCs, but MMP-13 in 16/31 keratoacanthomas and 10/15 SCCs, and MMP-10 in 28/31 keratoacanthomas and all cancers. MMP-9 was detected in the epithelium in 5/31 keratoacanthomas and 8/15 SCCs, whereas MMP-2 was only present in fibroblasts in both tumors. MMP-19 was upregulated in proliferating epithelium of keratoacanthomas as was p16. Cytoplasmic laminin-5gamma2 was particularly abundant in keratinocytes at the pushing border of MMP-13-positive keratoacanthomas. We conclude that although some MMPs (MMP-10 and -13) are abundantly expressed in keratoacanthomas, the presence of MMP-7 and -9 in their epithelial pushing border is rare and should raise suspicion of SCC. Further, the loss of MMP-19 and p16 could aid in making the differential diagnosis between well-differentiated SCC and keratoacanthoma. Frequent expression of the transformation-specific MMP-13 in keratoacanthomas suggests that they are not benign tumors but incomplete SCCs. Published online 12 May 2006.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699496     DOI: 10.1038/modpathol.3800633

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  5 in total

1.  The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study.

Authors:  Recep Bedir; Hasan Güçer; İbrahim Şehitoğlu; Cüneyt Yurdakul; Pelin Bağcı; Pelin Üstüner
Journal:  Balkan Med J       Date:  2016-03-01       Impact factor: 2.021

2.  Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls.

Authors:  Sonja Boyd; Kalle Tolvanen; Susanna Virolainen; Tiina Kuivanen; Lauri Kyllönen; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2007-11-22       Impact factor: 4.064

3.  Changes in matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinases (TIMP) expression profile in Crohn's disease after immunosuppressive treatment correlate with histological score and calprotectin values.

Authors:  Laura Mäkitalo; Taina Sipponen; Päivi Kärkkäinen; Kaija-Leena Kolho; Ulpu Saarialho-Kere
Journal:  Int J Colorectal Dis       Date:  2009-08-04       Impact factor: 2.571

4.  The Role of MMP8 in Cancer: A Systematic Review.

Authors:  Krista Juurikka; Georgina S Butler; Tuula Salo; Pia Nyberg; Pirjo Åström
Journal:  Int J Mol Sci       Date:  2019-09-11       Impact factor: 5.923

5.  Keratoacanthoma of the Lip: Activation of the mTOR Pathway, Tumor Suppressor Proteins, and Tumor Senescence.

Authors:  Caroline Siviero Dillenburg; Manoela Domingues Martins; Luise Meurer; Rogerio Moraes Castilho; Cristiane Helena Squarize
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.